Serum neurofilament light chain as a prognostic marker in postanoxic encephalopathy. 2019

Giulio Disanto, and Chiara Prosperetti, and Claudio Gobbi, and Christian Barro, and Zuzanna Michalak, and Tiziano Cassina, and Jens Kuhle, and Gabriele Casso, and Pamela Agazzi
Neurocenter of Southern Switzerland, Civic Hospital, Lugano, Switzerland.

Functional outcome in patients with postanoxic encephalopathy after cardiac arrest (CA) often remains unclear, and there is a strong need of new prognostication measures. We aimed at investigating serum neurofilament light (NfL) chain concentration in patients with a postanoxic encephalopathy after CA and its prognostic potential. Serum samples were prospectively collected at different time points after CA in consecutive patients admitted to the intensive care unit (ICU) of Ticino Cardiocentre (Lugano, Switzerland) between June 2017 and March 2018. Serum NfL concentration was measured using a single molecule array (SIMOA) assay. The association of NfL levels with time to return of spontaneous circulation (ROSC), serum neuronal specific enolase (NSE) concentration, time between CA and sample collection, electroencephalogram (EEG) pattern and clinical outcome (death status at one month) were explored. Fourteen patients experiencing 15 CAs were included in the study (median age = 58 (57-68) years, 8 males). Median serum NfL concentration was 1027.0 (25.5-6033.7) pg/ml. There were positive associations between serum NfL and time to ROSC (rho = 0.60, p < 0.0001), NSE concentration (rho = 0.76, p < 0.0001), and severity of brain damage as estimated by EEG, with the highest concentrations measured in patients with suppressed electrical activity (14,954.0 [9006.0-25,364.0] pg/ml). Neurofilament light concentration remained high in samples collected up to 17 days after CA. Median NfL levels were higher among dead than alive patients at one month (6401.7 [3768.5-15,573.3] vs 25.5 [25.2-75.4] pg/ml). High NfL levels performed better than NSE in predicting death status at one month (NfL area under the curve (AUC) = 0.98, 95% confidence interval (CI) = 0.94-1.00; NSE AUC = 0.80, 95% CI = 0.67-0.94). These results support the potential inclusion of serum NfL in the battery of prognostication measures to be used in patients with postanoxic encephalopathy in ICU settings. This article is part of the Special Issue "Proceedings of the 7th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures".

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D001927 Brain Diseases Pathologic conditions affecting the BRAIN, which is composed of the intracranial components of the CENTRAL NERVOUS SYSTEM. This includes (but is not limited to) the CEREBRAL CORTEX; intracranial white matter; BASAL GANGLIA; THALAMUS; HYPOTHALAMUS; BRAIN STEM; and CEREBELLUM. Intracranial Central Nervous System Disorders,Brain Disorders,CNS Disorders, Intracranial,Central Nervous System Disorders, Intracranial,Central Nervous System Intracranial Disorders,Encephalon Diseases,Encephalopathy,Intracranial CNS Disorders,Brain Disease,Brain Disorder,CNS Disorder, Intracranial,Encephalon Disease,Encephalopathies,Intracranial CNS Disorder
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000860 Hypoxia Sub-optimal OXYGEN levels in the ambient air of living organisms. Anoxia,Oxygen Deficiency,Anoxemia,Deficiency, Oxygen,Hypoxemia,Deficiencies, Oxygen,Oxygen Deficiencies
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D016900 Neurofilament Proteins Type III intermediate filament proteins that assemble into neurofilaments, the major cytoskeletal element in nerve axons and dendrites. They consist of three distinct polypeptides, the neurofilament triplet. Types I, II, and IV intermediate filament proteins form other cytoskeletal elements such as keratins and lamins. It appears that the metabolism of neurofilaments is disturbed in Alzheimer's disease, as indicated by the presence of neurofilament epitopes in the neurofibrillary tangles, as well as by the severe reduction of the expression of the gene for the light neurofilament subunit of the neurofilament triplet in brains of Alzheimer's patients. (Can J Neurol Sci 1990 Aug;17(3):302) Neurofilament Protein,Heavy Neurofilament Protein,Neurofilament Triplet Proteins,Neurofilament Protein, Heavy,Protein, Heavy Neurofilament,Protein, Neurofilament,Proteins, Neurofilament,Proteins, Neurofilament Triplet,Triplet Proteins, Neurofilament

Related Publications

Giulio Disanto, and Chiara Prosperetti, and Claudio Gobbi, and Christian Barro, and Zuzanna Michalak, and Tiziano Cassina, and Jens Kuhle, and Gabriele Casso, and Pamela Agazzi
December 2019, The Lancet. Neurology,
Giulio Disanto, and Chiara Prosperetti, and Claudio Gobbi, and Christian Barro, and Zuzanna Michalak, and Tiziano Cassina, and Jens Kuhle, and Gabriele Casso, and Pamela Agazzi
June 2021, Scientific reports,
Giulio Disanto, and Chiara Prosperetti, and Claudio Gobbi, and Christian Barro, and Zuzanna Michalak, and Tiziano Cassina, and Jens Kuhle, and Gabriele Casso, and Pamela Agazzi
March 2010, Multiple sclerosis (Houndmills, Basingstoke, England),
Giulio Disanto, and Chiara Prosperetti, and Claudio Gobbi, and Christian Barro, and Zuzanna Michalak, and Tiziano Cassina, and Jens Kuhle, and Gabriele Casso, and Pamela Agazzi
May 2024, European journal of epidemiology,
Giulio Disanto, and Chiara Prosperetti, and Claudio Gobbi, and Christian Barro, and Zuzanna Michalak, and Tiziano Cassina, and Jens Kuhle, and Gabriele Casso, and Pamela Agazzi
April 2021, Journal of neurology,
Giulio Disanto, and Chiara Prosperetti, and Claudio Gobbi, and Christian Barro, and Zuzanna Michalak, and Tiziano Cassina, and Jens Kuhle, and Gabriele Casso, and Pamela Agazzi
March 2022, The Lancet. Neurology,
Giulio Disanto, and Chiara Prosperetti, and Claudio Gobbi, and Christian Barro, and Zuzanna Michalak, and Tiziano Cassina, and Jens Kuhle, and Gabriele Casso, and Pamela Agazzi
June 2020, Neurology,
Giulio Disanto, and Chiara Prosperetti, and Claudio Gobbi, and Christian Barro, and Zuzanna Michalak, and Tiziano Cassina, and Jens Kuhle, and Gabriele Casso, and Pamela Agazzi
October 2023, European journal of neurology,
Giulio Disanto, and Chiara Prosperetti, and Claudio Gobbi, and Christian Barro, and Zuzanna Michalak, and Tiziano Cassina, and Jens Kuhle, and Gabriele Casso, and Pamela Agazzi
January 2021, Frontiers in neuroscience,
Giulio Disanto, and Chiara Prosperetti, and Claudio Gobbi, and Christian Barro, and Zuzanna Michalak, and Tiziano Cassina, and Jens Kuhle, and Gabriele Casso, and Pamela Agazzi
April 2023, Journal of neurology,
Copied contents to your clipboard!